269 related articles for article (PubMed ID: 34685407)
1. Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review.
Gatteschi L; Iannopollo M; Gonfiotti A
Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685407
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
3. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
6. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review.
Efil SC; Bilgin B; Ceylan F; Karakaş H; Karahan İ; Özsan SN; Kosku H; Yaman Ş; Bülent Akıncı M; Dede DŞ; Yalçın B; Nahit Şendur MA
J Oncol Pharm Pract; 2024 Jun; ():10781552241260864. PubMed ID: 38860323
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
Chiu LC; Lin SM; Lo YL; Kuo SC; Yang CT; Hsu PC
Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34201650
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone.
Tang WF; Ye HY; Tang X; Su JW; Xu KM; Zhong WZ; Liang Y
Front Oncol; 2023; 13():1063183. PubMed ID: 36776323
[TBL] [Abstract][Full Text] [Related]
10. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety.
Shao L; Lou G
J Thorac Dis; 2022 Sep; 14(9):3565-3574. PubMed ID: 36245597
[TBL] [Abstract][Full Text] [Related]
13. The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
Li F; Chen Y; Wu J; Li C; Chen S; Zhu Z; Qin W; Liu M; Hu B; Liu S; Zhong W
Chronic Dis Transl Med; 2022 Jun; 8(2):100-111. PubMed ID: 35774424
[TBL] [Abstract][Full Text] [Related]
14. Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors.
Rojas F; Parra ER; Wistuba II; Haymaker C; Solis Soto LM
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681755
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.
Shukla N; Hanna N
Lung Cancer (Auckl); 2021; 12():51-60. PubMed ID: 34234606
[TBL] [Abstract][Full Text] [Related]
16. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
18. An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy.
Verma S; Breadner D; Mittal A; Palma DA; Nayak R; Raphael J; Vincent M
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610980
[TBL] [Abstract][Full Text] [Related]
19. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.
Xu Z; Zou Z; Hao X; Xing P; Li J
Cancer Innov; 2023 Feb; 2(1):65-78. PubMed ID: 38090369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
